Workflow
海外配电市场拓展
icon
Search documents
三星医疗:突破西欧高端配网市场,海外配电订单有望加速释放-20260306
SINOLINK SECURITIES· 2026-03-06 10:24
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][11]. Core Insights - The company has signed a framework contract with the Dutch Enexis power authority worth €117 million, marking its entry into the high-end distribution market in Western Europe [3]. - The European distribution network investment is driven by three main factors: electrification, aging infrastructure replacement, and the integration of renewable energy sources [3]. - The company is expected to see significant growth in its distribution segment, particularly in overseas markets, with a projected compound annual growth rate (CAGR) of 1.3% for electricity demand from 2024 to 2027, accelerating to 2.0% from 2027 to 2030 [3][4]. Summary by Relevant Sections Business Analysis - The electrification trend, driven by electric vehicles, heat pumps, and data centers, is expected to lead to a gradual recovery in electricity demand in Europe starting in 2025 [3]. - Approximately 30% of the European distribution network's equipment is over 40 years old, necessitating upgrades [3]. - The share of renewable energy in Europe is projected to increase from 34% in 2019 to 47% in 2024, requiring a shift from a centralized to a distributed grid structure [3]. Financial Forecasts - The company is projected to achieve a net profit of RMB 17.8 billion, RMB 24.0 billion, and RMB 30.8 billion for the years 2025 to 2027, representing year-on-year growth rates of -21%, +35%, and +28% respectively [5]. - The current stock price corresponds to price-to-earnings (P/E) ratios of 21, 16, and 12 for the years 2025 to 2027 [5]. Market Position - The company has established a strong presence in the overseas distribution market, with significant investments in research and development to meet the stringent standards and low-carbon requirements of the European market [4]. - The successful bid for the Enexis contract indicates that the company's products are competitive on a global scale, enhancing its order book and market position [4].
三星医疗(601567):突破西欧高端配网市场,海外配电订单有望加速释放
SINOLINK SECURITIES· 2026-03-06 08:16
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][11]. Core Insights - The company has signed a framework contract with the Dutch Enexis for transformers, totaling €117 million, marking its entry into the high-end distribution market in Western Europe [3]. - The European distribution network investment is driven by three main factors: electrification, aging infrastructure replacement, and the integration of renewable energy sources [3]. - The company is expected to see significant growth in its distribution segment, particularly in overseas markets, with a projected compound annual growth rate (CAGR) of 1.3% for electricity demand from 2024 to 2027, accelerating to 2.0% from 2027 to 2030 [3][4]. Summary by Relevant Sections Business Analysis - The electrification trend, driven by electric vehicles, heat pumps, and data centers, is expected to lead to a gradual recovery in electricity demand in Europe starting in 2025 [3]. - Approximately 30% of the European distribution network's equipment is over 40 years old, necessitating upgrades [3]. - The share of renewable energy in Europe is projected to increase from 34% in 2019 to 47% in 2024, requiring a shift from a centralized to a distributed grid structure [3]. Financial Forecasts - The company is projected to achieve a net profit attributable to shareholders of RMB 1.78 billion, RMB 2.40 billion, and RMB 3.08 billion for the years 2025 to 2027, representing year-on-year growth rates of -21%, +35%, and +28% respectively [5][8]. - The price-to-earnings (P/E) ratio is expected to be 21, 16, and 12 times for the years 2025 to 2027 [5]. Market Position - The company has established a strong presence in the overseas distribution market, with significant investments in research and development to meet the stringent standards and low-carbon requirements of the European market [4]. - The successful bid for the Enexis contract indicates that the company's products are competitive on a global scale, enhancing its order book and market position [4].
三星医疗(601567):配电出海持续高景气,电表新规落地带动价格修复
Guoxin Securities· 2025-11-11 07:06
Investment Rating - The investment rating for the company is "Outperform the Market" [5][3]. Core Views - The company has experienced a 16% decline in performance over the first three quarters, with revenue at 11.08 billion yuan, a year-on-year increase of 6.19%, and a net profit of 1.528 billion yuan, down 15.85% year-on-year [9][3]. - The company is expected to gradually recover over the next six months as the negative factors in the domestic electric meter, distribution, and photovoltaic industries are largely exhausted [2][21]. - The recent opening of the third batch of electric meter tenders by the State Grid has led to a noticeable price recovery, benefiting leading electric meter companies [2][21]. - The company has a robust order backlog, with total orders amounting to 17.914 billion yuan, a year-on-year increase of 14.69%, and overseas distribution orders at 2.169 billion yuan, up 125.45% year-on-year [22][2]. Financial Performance Summary - For the first three quarters, the company reported a revenue of 11.08 billion yuan, with a gross margin of 28.46%, down 7.75 percentage points year-on-year, and a net margin of 13.60%, down 3.87 percentage points year-on-year [9][21]. - In Q3 alone, the company achieved a revenue of 3.108 billion yuan, a year-on-year decrease of 9.56% and a quarter-on-quarter decrease of 28.42%, with a net profit of 298 million yuan, down 55.22% year-on-year and 59.74% quarter-on-quarter [21][17]. - The company has adjusted its profit forecast for 2025-2027, expecting net profits of 1.875 billion, 2.473 billion, and 3.072 billion yuan respectively, with corresponding PE ratios of 20, 15, and 12 times [3][22].
三星医疗(601567):2025年中报点评:提质增效效果显著,业绩基本符合市场预期
Soochow Securities· 2025-08-22 05:26
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in the first half of 2025 is in line with market expectations, with significant improvements in quality and efficiency [8] - The company has achieved robust growth in its power distribution business, particularly in overseas markets, which is becoming a key growth driver [8] - The rehabilitation hospital business faces some pressure, but long-term demand remains strong [8] - The company has effectively controlled costs, leading to a notable reduction in expenses [8] - The long-term outlook for the overseas power distribution market is positive, with strong competitive advantages [8] Financial Summary - Total revenue for 2023 is projected at 11,463 million, with a year-on-year growth of 25.99% [1] - Net profit attributable to shareholders for 2023 is expected to be 1,904 million, reflecting a year-on-year increase of 100.79% [1] - The earnings per share (EPS) for 2023 is estimated at 1.35 yuan, with a price-to-earnings (P/E) ratio of 18.20 [1] - The company anticipates total revenue of 18,034 million in 2025, with a year-on-year growth of 23.51% [1] - The net profit attributable to shareholders for 2025 is projected at 2,511 million, with a year-on-year growth of 11.14% [1] - The EPS for 2025 is expected to be 1.79 yuan, with a P/E ratio of 13.80 [1]